Contribution of Gut Microbiota to Immunological Changes in Alzheimer's Disease.

Autor:	van Olst L; Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, Netherlands., Roks SJM; Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, Netherlands., Kamermans A; Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, Netherlands., Verhaar BJH; Department of Internal Medicine, Section Geriatrics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands., van der Geest AM; Vrije Universiteit Amsterdam, Athena Institute, Amsterdam, Netherlands., Muller M; Department of Internal Medicine, Section Geriatrics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands., van der Flier WM; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands., de Vries HE; Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Centers, Amsterdam Neuroscience, Amsterdam, Netherlands.; Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam, Netherlands.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 May 31; Vol. 12, pp. 683068. Date of Electronic Publication: 2021 May 31 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.683068
Abstrakt:	Emerging evidence suggests that both central and peripheral immunological processes play an important role in the pathogenesis of Alzheimer's disease (AD), but regulatory mechanisms remain unknown. The gut microbiota and its key metabolites are known to affect neuroinflammation by modulating the activity of peripheral and brain-resident immune cells, yet an overview on how the gut microbiota contribute to immunological alterations in AD is lacking. In this review, we discuss current literature on microbiota composition in AD patients and relevant animal models. Next, we highlight how microbiota and their metabolites may contribute to peripheral and central immunological changes in AD. Finally, we offer a future perspective on the translation of these findings into clinical practice by targeting gut microbiota to modulate inflammation in AD. Since we find that gut microbiota alterations in AD can induce peripheral and central immunological changes via the release of microbial metabolites, we propose that modulating their composition may alter ongoing inflammation and could therefore be a promising future strategy to fight progression of AD. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 van Olst, Roks, Kamermans, Verhaar, van der Geest, Muller, van der Flier and de Vries.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu